{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:11Z","timestamp":1786480211558,"version":"build-2736575974"},"reference-count":197,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Long-term kidney allograft survival remains an important clinical challenge. Although immune-mediated injury, particularly antibody mediated rejection, is associated with long-term graft loss, nonimmune mechanisms also drive chronic allograft failure. Podocytes are essential components of the glomerular filtration barrier, and their injury in the transplant setting may accelerate graft loss. In this review, we will discuss mechanisms of podocyte injury contributing to chronic graft failure including immune injury and nonimmune mechanisms such as immunosuppressive drug exposure and transplant-specific biomechanical changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000001091","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:03:29Z","timestamp":1764954209000},"page":"1405-1415","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of Podocyte Injury in Kidney Allografts"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1753-6380","authenticated-orcid":false,"given":"Gabriel C.","family":"Barsotti","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9567-4299","authenticated-orcid":false,"given":"Madhav C.","family":"Menon","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-9425","authenticated-orcid":false,"given":"Abhijit","family":"Naik","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-7816","authenticated-orcid":false,"given":"Arundati","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"11","key":"B1-20260625","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure","volume":"9","author":"Einecke","year":"2009","journal-title":"Am J Transplant."},{"issue":"1","key":"B2-20260625","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ajt.14431","article-title":"Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury","volume":"18","author":"Stegall","year":"2018","journal-title":"Am J Transplant."},{"issue":"7","key":"B3-20260625","doi-asserted-by":"crossref","first-page":"e86943","DOI":"10.1172\/jci.insight.86943","article-title":"Quantitative podocyte parameters predict human native kidney and allograft half-lives","volume":"1","author":"Naik","year":"2016","journal-title":"JCI Insight."},{"key":"B4-20260625","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev-physiol-020911-153238","article-title":"Cell biology and pathology of podocytes","volume":"74","author":"Greka","year":"2012","journal-title":"Annu Rev Physiol."},{"key":"B5-20260625","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7255.1","article-title":"Podocytes","volume":"5","author":"Reiser","year":"2016","journal-title":"F1000Res."},{"issue":"3","key":"B6-20260625","doi-asserted-by":"crossref","first-page":"407","DOI":"10.34067\/KID.0008212021","article-title":"Urinary podocyte biomarkers and glomerular histologic change","volume":"3","author":"Inoue","year":"2022","journal-title":"Kidney360."},{"issue":"5","key":"B7-20260625","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest."},{"issue":"11","key":"B8-20260625","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2010.64","article-title":"Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease","volume":"77","author":"Veron","year":"2010","journal-title":"Kidney Int."},{"issue":"5","key":"B9-20260625","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1681\/ASN.2013020195","article-title":"Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis","volume":"25","author":"Lenoir","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B10-20260625","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1681\/ASN.2012020133","article-title":"Podocytes are nonhematopoietic professional antigen-presenting cells","volume":"24","author":"Goldwich","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B11-20260625","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfq617","article-title":"The podocyte as a direct target of immunosuppressive agents","volume":"26","author":"Sch\u00f6nenberger","year":"2011","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B12-20260625","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/dmrr.1164","article-title":"The role of metabolic and haemodynamic factors in podocyte injury in diabetes","volume":"27","author":"Stieger","year":"2011","journal-title":"Diabetes Metab Res Rev."},{"issue":"17","key":"B13-20260625","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMc1202500","article-title":"Resolution of recurrent focal segmental glomerulosclerosis after retransplantation","volume":"366","author":"Gallon","year":"2012","journal-title":"N Engl J Med."},{"issue":"3","key":"B14-20260625","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00467-016-3358-9","article-title":"Mechanical challenges to the glomerular filtration barrier: adaptations and pathway to sclerosis","volume":"32","author":"Kriz","year":"2017","journal-title":"Pediatr Nephrol."},{"issue":"10","key":"B15-20260625","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1681\/ASN.2005010055","article-title":"Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene","volume":"16","author":"Wharram","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B16-20260625","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1681\/ASN.2013050452","article-title":"Unraveling the role of podocyte turnover in glomerular aging and injury","volume":"25","author":"Wanner","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B17-20260625","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1681\/ASN.2015121340","article-title":"Validation of a three-dimensional method for counting and sizing podocytes in whole glomeruli","volume":"27","author":"Puelles","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B18-20260625","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1681\/ASN.2012030271","article-title":"Growth-dependent podocyte failure causes glomerulosclerosis","volume":"23","author":"Fukuda","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B19-20260625","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1681\/ASN.2017020174","article-title":"FSGS as an adaptive response to growth-induced podocyte stress","volume":"28","author":"Nishizono","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B20-20260625","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1172\/JCI119163","article-title":"Podocyte loss and progressive glomerular injury in type II diabetes","volume":"99","author":"Pagtalunan","year":"1997","journal-title":"J Clin Invest."},{"issue":"4","key":"B21-20260625","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1046\/j.1523-1755.2002.00269.x","article-title":"Podocytopenia and disease severity in IgA nephropathy","volume":"61","author":"Lemley","year":"2002","journal-title":"Kidney Int."},{"issue":"10","key":"B22-20260625","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1681\/ASN.2005050488","article-title":"Podocyte hypertrophy, \u201cadaptation,\u201d and \u201cdecompensation\u201d associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction","volume":"16","author":"Wiggins","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B23-20260625","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41556-018-0092-5","article-title":"A brief history of autophagy from cell biology to physiology and disease","volume":"20","author":"Mizushima","year":"2018","journal-title":"Nat Cell Biol."},{"issue":"2","key":"B24-20260625","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol Cell."},{"issue":"5","key":"B25-20260625","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cmet.2008.02.011","article-title":"Hypothalamic CaMKK2 contributes to the regulation of energy balance","volume":"7","author":"Anderson","year":"2008","journal-title":"Cell Metab."},{"issue":"6","key":"B26-20260625","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/emboj.2009.8","article-title":"TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells","volume":"28","author":"Herrero-Mart\u00edn","year":"2009","journal-title":"EMBO J."},{"issue":"5","key":"B27-20260625","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell."},{"issue":"5","key":"B28-20260625","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.ekir.2024.02.006","article-title":"Rationale and design of a phase 2, double-blind, placebo-controlled, randomized trial evaluating AMP kinase-activation by metformin in focal segmental glomerulosclerosis","volume":"9","author":"Barsotti","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B29-20260625","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI73939","article-title":"mTOR: a pharmacologic target for autophagy regulation","volume":"125","author":"Kim","year":"2015","journal-title":"J Clin Invest."},{"issue":"2","key":"B30-20260625","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0306-3356(21)00017-0","article-title":"The treatment of gastrointestinal disease in pregnancy","volume":"13","author":"Atlay","year":"1986","journal-title":"Clin Obstet Gynaecol."},{"issue":"5","key":"B31-20260625","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/emboj.2012.32","article-title":"A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB","volume":"31","author":"Settembre","year":"2012","journal-title":"EMBO J."},{"issue":"6","key":"B32-20260625","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4161\/auto.19653","article-title":"MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB","volume":"8","author":"Martina","year":"2012","journal-title":"Autophagy."},{"issue":"18","key":"B33-20260625","doi-asserted-by":"crossref","first-page":"e99271","DOI":"10.1172\/jci.insight.99271","article-title":"mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans","volume":"4","author":"Puelles","year":"2019","journal-title":"JCI Insight."},{"key":"B34-20260625","doi-asserted-by":"crossref","first-page":"108869","DOI":"10.1016\/j.clim.2021.108869","article-title":"Seven novel podocyte autoantibodies were identified to diagnosis a new disease subgroup-autoimmune podocytopathies","volume":"232","author":"Ye","year":"2021","journal-title":"Clin Immunol."},{"issue":"1","key":"B35-20260625","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting Nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B36-20260625","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med."},{"issue":"4","key":"B37-20260625","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.kint.2024.07.022","article-title":"Pre-transplant Anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft","volume":"106","author":"Batal","year":"2024","journal-title":"Kidney Int."},{"issue":"2","key":"B38-20260625","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B39-20260625","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"issue":"2","key":"B40-20260625","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B41-20260625","doi-asserted-by":"crossref","first-page":"593288","DOI":"10.3389\/fimmu.2021.593288","article-title":"Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy","volume":"12","author":"Tesar","year":"2021","journal-title":"Front Immunol."},{"issue":"24","key":"B42-20260625","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"B43-20260625","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"issue":"5","key":"B44-20260625","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"issue":"7","key":"B45-20260625","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B46-20260625","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ajt.2024.01.036","article-title":"Recurrence of membranous nephropathy after kidney transplantation: a multicenter retrospective cohort study","volume":"24","author":"Hullekes","year":"2024","journal-title":"Am J Transplant."},{"issue":"3","key":"B47-20260625","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5500\/wjt.v4.i3.176","article-title":"Kidney transplantation in patients with systemic lupus erythematosus","volume":"4","author":"Lionaki","year":"2014","journal-title":"World J Transplant."},{"issue":"6","key":"B48-20260625","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2025.03.044","article-title":"The clinicopathologic characteristics of recurrent lupus nephritis post-transplant using surveillance and indication biopsies","volume":"10","author":"Gonzalez Suarez","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B49-20260625","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40620-017-0463-1","article-title":"Lupus podocytopathy: a distinct entity of lupus nephritis","volume":"31","author":"Chen","year":"2018","journal-title":"J Nephrol."},{"issue":"1","key":"B50-20260625","first-page":"49","article-title":"Diabetic kidney disease: world wide difference of prevalence and risk factors","volume":"5","author":"Gheith","year":"2016","journal-title":"J Nephropharmacol."},{"issue":"2","key":"B51-20260625","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/biomedicines11020470","article-title":"Diabetic kidney disease in post-transplant diabetes mellitus: causes, treatment and outcomes","volume":"11","author":"Lim","year":"2023","journal-title":"Biomedicines."},{"issue":"suppl 1","key":"B52-20260625","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1681\/ASN.2004110970","article-title":"Pathogenetic mechanisms of diabetic nephropathy","volume":"16","author":"Schena","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"10 suppl l","key":"B53-20260625","first-page":"SS3","article-title":"New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation."},{"key":"B54-20260625","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fendo.2014.00141","article-title":"Diabetes mellitus in the transplanted kidney","volume":"5","author":"Peev","year":"2014","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"B55-20260625","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-200301150-00012","article-title":"Recurrent and de novo diabetic nephropathy in renal allografts","volume":"75","author":"Bhalla","year":"2003","journal-title":"Transplantation."},{"issue":"2","key":"B56-20260625","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant."},{"issue":"7","key":"B57-20260625","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/TP.0b013e31825f4434","article-title":"Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses","volume":"94","author":"Valderhaug","year":"2012","journal-title":"Transplantation."},{"issue":"3","key":"B58-20260625","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/TP.0b013e318160ee42","article-title":"Posttransplant diabetes mellitus and acute rejection: impact on kidney transplant outcome","volume":"85","author":"Matas","year":"2008","journal-title":"Transplantation."},{"issue":"3","key":"B59-20260625","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00007890-199203000-00014","article-title":"Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man","volume":"53","author":"Ekstrand","year":"1992","journal-title":"Transplantation."},{"issue":"3","key":"B60-20260625","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/tri.12907","article-title":"The impact of kidney transplantation on insulin sensitivity","volume":"30","author":"J\u00f8rgensen","year":"2017","journal-title":"Transpl Int."},{"issue":"9","key":"B61-20260625","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc12-2441","article-title":"Glucose metabolism after renal transplantation","volume":"36","author":"Hecking","year":"2013","journal-title":"Diabetes Care."},{"issue":"4","key":"B62-20260625","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2337\/dc15-2383","article-title":"GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes","volume":"39","author":"Halden","year":"2016","journal-title":"Diabetes Care."},{"issue":"3","key":"B63-20260625","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41574-018-0137-7","article-title":"Post-transplant diabetes mellitus in patients with solid organ transplants","volume":"15","author":"Jenssen","year":"2019","journal-title":"Nat Rev Endocrinol."},{"issue":"6","key":"B64-20260625","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.11650918","article-title":"Hypoglycemia in people with type 2 diabetes and CKD","volume":"14","author":"Ahmad","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B65-20260625","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","author":"van Raalte","year":"2009","journal-title":"Eur J Clin Invest."},{"issue":"7","key":"B66-20260625","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1464-5491.2012.03617.x","article-title":"Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation","volume":"29","author":"Dong","year":"2012","journal-title":"Diabet Med."},{"issue":"4","key":"B67-20260625","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/diabetes.54.4.1090","article-title":"Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion","volume":"54","author":"Ullrich","year":"2005","journal-title":"Diabetes."},{"issue":"1","key":"B68-20260625","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.metabol.2005.06.023","article-title":"Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets","volume":"55","author":"Zawalich","year":"2006","journal-title":"Metabolism."},{"issue":"5 Pt 2","key":"B69-20260625","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1262-3636(06)72809-9","article-title":"Immunosuppressive drug-induced diabetes","volume":"32","author":"Penfornis","year":"2006","journal-title":"Diabetes Metab."},{"issue":"6","key":"B70-20260625","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant."},{"issue":"4","key":"B71-20260625","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant."},{"issue":"10","key":"B72-20260625","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/01.tp.0000181142.82649.e3","article-title":"Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus","volume":"80","author":"Numakura","year":"2005","journal-title":"Transplantation."},{"issue":"1","key":"B73-20260625","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-6143.2012.04281.x","article-title":"Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation","volume":"13","author":"Isakova","year":"2013","journal-title":"Am J Transplant."},{"issue":"7","key":"B74-20260625","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients","volume":"19","author":"Johnston","year":"2008","journal-title":"J Am Soc Nephrol."},{"issue":"6 suppl l","key":"B75-20260625","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.transproceed.2009.06.159","article-title":"Mammalian target of rapamycin and diabetes: what does the current evidence tell us?","volume":"41","author":"Vodenik","year":"2009","journal-title":"Transpl Proc."},{"issue":"2","key":"B76-20260625","doi-asserted-by":"crossref","first-page":"E365","DOI":"10.1152\/ajpendo.00390.2004","article-title":"Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity","volume":"288","author":"Radu","year":"2005","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"1","key":"B77-20260625","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/JOE-09-0216","article-title":"Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism","volume":"204","author":"Shimodahira","year":"2010","journal-title":"J Endocrinol."},{"issue":"8","key":"B78-20260625","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.34067\/KID.0000862021","article-title":"Post-transplant diabetes mellitus in kidney transplant recipients: a multicenter study","volume":"2","author":"Malik","year":"2021","journal-title":"Kidney360."},{"issue":"3","key":"B79-20260625","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ndt\/gfae185","article-title":"Prognostic impact of post-transplant diabetes mellitus in kidney allograft recipients: a meta-analysis","volume":"40","author":"Kanbay","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B80-20260625","doi-asserted-by":"crossref","first-page":"e14922","DOI":"10.1111\/ctr.14922","article-title":"Sweet and simple as syrup: a review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation","volume":"37","author":"Lawrence","year":"2023","journal-title":"Clin Transplant."},{"issue":"9","key":"B81-20260625","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation."},{"issue":"6","key":"B82-20260625","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.transproceed.2024.02.026","article-title":"Combination of SGLT2 inhibitors and GLP-1 receptor agonists in PTDM treatment in kidney transplant recipients: synergistic effect with added value in terms of nephroprotection","volume":"56","author":"Juric","year":"2024","journal-title":"Transpl Proc."},{"issue":"6","key":"B83-20260625","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2024.06.014","article-title":"Viral nephropathies: core curriculum 2024","volume":"84","author":"Yau","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B84-20260625","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000531434","article-title":"Viral glomerulopathy","volume":"3","author":"Deoliveira","year":"2023","journal-title":"Glomerular Dis."},{"issue":"7","key":"B85-20260625","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1542\/pir.16.7.278","article-title":"Poststreptococcal acute glomerulonephritis","volume":"16","author":"Simckes","year":"1995","journal-title":"Pediatr Rev."},{"issue":"1","key":"B86-20260625","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pcl.2018.08.005","article-title":"Infection-related glomerulonephritis","volume":"66","author":"Hunt","year":"2019","journal-title":"Pediatr Clin North Am."},{"issue":"6","key":"B87-20260625","doi-asserted-by":"crossref","first-page":"e13169","DOI":"10.1111\/tid.13169","article-title":"Cytomegalovirus renal infection: rare manifestation of a common post-transplant viral infection-A case series","volume":"21","author":"Posadas Salas","year":"2019","journal-title":"Transpl Infect Dis."},{"issue":"3","key":"B88-20260625","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.humpath.2003.09.009","article-title":"Glomerular changes in BK virus nephropathy","volume":"35","author":"Celik","year":"2004","journal-title":"Hum Pathol."},{"issue":"8","key":"B89-20260625","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/v14081616","article-title":"BK virus nephropathy in kidney transplantation: a state-of-the-art review","volume":"14","author":"Kant","year":"2022","journal-title":"Viruses."},{"key":"B90-20260625","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/IJNRD.S391779","article-title":"Post-transplant glomerulonephritis: challenges and solutions","volume":"17","author":"de Sousa","year":"2024","journal-title":"Int J Nephrol Renovasc Dis."},{"issue":"4","key":"B91-20260625","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/00007890-198804000-00008","article-title":"Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy","volume":"45","author":"Boyce","year":"1988","journal-title":"Transplantation."},{"issue":"9","key":"B92-20260625","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2020060802","article-title":"Kidney biopsy findings in patients with COVID-19","volume":"31","author":"Kudose","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B93-20260625","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1681\/ASN.2020050699","article-title":"COVID-19-Associated kidney injury: a case series of kidney biopsy findings","volume":"31","author":"Sharma","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B94-20260625","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MS9.0000000000000107","article-title":"Collapsing focal segmental glomerulosclerosis secondary to COVID-19: a systematic review and meta-analysis","volume":"85","author":"Qamar","year":"2023","journal-title":"Ann Med Surg (Lond)."},{"issue":"1","key":"B95-20260625","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/vaccines12010062","article-title":"Tip lesion most frequent FSGS variant related to COVID-19 vaccine: two case reports and literature review","volume":"12","author":"Ara\u00fajo","year":"2024","journal-title":"Vaccines (Basel)."},{"issue":"3","key":"B96-20260625","doi-asserted-by":"crossref","first-page":"F326","DOI":"10.1152\/ajprenal.00647.2013","article-title":"APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability","volume":"307","author":"Lan","year":"2014","journal-title":"Am J Physiol Renal Physiol."},{"key":"B97-20260625","doi-asserted-by":"crossref","first-page":"800074","DOI":"10.3389\/fimmu.2021.800074","article-title":"Collapsing focal segmental glomerulosclerosis in viral infections","volume":"12","author":"Muehlig","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"B98-20260625","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40620-020-00935-6","article-title":"COVID-19-related collapsing glomerulopathy revealing a rare risk variant of APOL1: lessons for the clinical nephrologist","volume":"34","author":"Laboux","year":"2021","journal-title":"J Nephrol."},{"issue":"4","key":"B99-20260625","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.xkme.2020.05.004","article-title":"COVID-19-Related glomerulopathy: a report of 2 cases of collapsing focal segmental glomerulosclerosis","volume":"2","author":"Magoon","year":"2020","journal-title":"Kidney Med."},{"issue":"1","key":"B100-20260625","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.2020060804","article-title":"COVID-19-associated glomerular disease","volume":"32","author":"Shetty","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"B101-20260625","doi-asserted-by":"crossref","first-page":"13365","DOI":"10.3389\/ti.2024.13365","article-title":"Re-Evaluating the transplant glomerulopathy lesion-beyond donor-specific antibodies","volume":"37","author":"Chutani","year":"2024","journal-title":"Transpl Int."},{"issue":"4","key":"B102-20260625","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.kint.2021.11.031","article-title":"Glomerular endothelial cell-podocyte stresses and crosstalk in structurally normal kidney transplants","volume":"101","author":"Menon","year":"2022","journal-title":"Kidney Int."},{"issue":"9","key":"B103-20260625","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant."},{"issue":"5","key":"B104-20260625","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.humimm.2011.02.002","article-title":"Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy","volume":"72","author":"Eng","year":"2011","journal-title":"Hum Immunol."},{"issue":"5","key":"B105-20260625","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/TP.0b013e3181837626","article-title":"Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels","volume":"86","author":"Issa","year":"2008","journal-title":"Transplantation."},{"issue":"3","key":"B106-20260625","doi-asserted-by":"crossref","first-page":"e12862","DOI":"10.1111\/xen.12862","article-title":"Late graft failure of pig-to-rhesus renal xenografts has features of glomerulopathy and recipients have anti-swine leukocyte antigen class I and class II antibodies","volume":"31","author":"Ladowski","year":"2024","journal-title":"Xenotransplantation."},{"issue":"12","key":"B107-20260625","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1681\/ASN.2018111169","article-title":"Anti-donor MHC class II alloantibody induces glomerular injury in Mouse renal allografts subjected to prolonged cold ischemia","volume":"30","author":"Gorbacheva","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B108-20260625","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.kint.2018.08.041","article-title":"In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection","volume":"95","author":"Yagisawa","year":"2019","journal-title":"Kidney Int."},{"issue":"7","key":"B109-20260625","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1600-6143.2007.01836.x","article-title":"Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause","volume":"7","author":"Sis","year":"2007","journal-title":"Am J Transplant."},{"issue":"6","key":"B110-20260625","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1681\/ASN.2010111183","article-title":"Antibodies reactive to non-HLA antigens in transplant glomerulopathy","volume":"22","author":"Dinavahi","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B111-20260625","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/01.ASN.0000127988.42710.A7","article-title":"Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats","volume":"15","author":"Hoffmann","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B112-20260625","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection","volume":"352","author":"Dragun","year":"2005","journal-title":"N Engl J Med."},{"issue":"1","key":"B113-20260625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12882-020-01910-w","article-title":"Angiotensin II receptor 1 antibodies associate with post-transplant focal segmental glomerulosclerosis and proteinuria","volume":"21","author":"Abuzeineh","year":"2020","journal-title":"BMC Nephrol."},{"issue":"2","key":"B114-20260625","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-6143.2005.00690.x","article-title":"Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy","volume":"5","author":"Joosten","year":"2005","journal-title":"Am J Transplant."},{"issue":"13","key":"B115-20260625","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa067160","article-title":"Antibodies against MICA antigens and kidney-transplant rejection","volume":"357","author":"Zou","year":"2007","journal-title":"N Engl J Med."},{"issue":"6","key":"B116-20260625","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1681\/ASN.2012080814","article-title":"MICA variant promotes allosensitization after kidney transplantation","volume":"24","author":"Tonnerre","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B117-20260625","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat Commun."},{"issue":"21","key":"B118-20260625","doi-asserted-by":"crossref","first-page":"e185687","DOI":"10.1172\/jci.insight.185687","article-title":"High-dimensional analysis of NK cells in kidney transplantation uncovers subsets associated with antibody-independent graft dysfunction","volume":"9","author":"Ruan","year":"2024","journal-title":"JCI Insight."},{"issue":"8","key":"B119-20260625","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJMoa2408835","article-title":"Microvascular inflammation of kidney allografts and clinical outcomes","volume":"392","author":"Sablik","year":"2025","journal-title":"N Engl J Med."},{"issue":"4","key":"B120-20260625","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.ki.5002655","article-title":"Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts)","volume":"73","author":"D'Agati","year":"2008","journal-title":"Kidney Int."},{"issue":"6","key":"B121-20260625","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1681\/ASN.2014030287","article-title":"The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective","volume":"26","author":"Yang","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B122-20260625","doi-asserted-by":"crossref","first-page":"e14457","DOI":"10.1111\/ctr.14457","article-title":"Urine marker analysis identifies evidence for persistent glomerular podocyte injury across allograft lifespan","volume":"35","author":"Naik","year":"2021","journal-title":"Clin Transplant."},{"issue":"3","key":"B123-20260625","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.kint.2020.03.038","article-title":"Podocyte stress and detachment measured in urine are related to mean arterial pressure in healthy humans","volume":"98","author":"Naik","year":"2020","journal-title":"Kidney Int."},{"issue":"2","key":"B124-20260625","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/ndt\/5.2.123","article-title":"Compensatory renal growth: role of growth hormone and insulin-like growth factor-I","volume":"5","author":"el Nahas","year":"1990","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"B125-20260625","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF00277413","article-title":"Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats","volume":"31","author":"Flyvbjerg","year":"1988","journal-title":"Diabetologia."},{"issue":"11","key":"B126-20260625","doi-asserted-by":"crossref","first-page":"e188485","DOI":"10.1172\/jci.insight.188485","article-title":"The growth hormone\/IGF-1 axis is a risk factor for long-term kidney allograft failure","volume":"10","author":"Cusick","year":"2025","journal-title":"JCI Insight."},{"issue":"1","key":"B127-20260625","doi-asserted-by":"crossref","first-page":"19605","DOI":"10.1038\/s41598-021-99124-z","article-title":"Critical timing of ACEi initiation prevents compensatory glomerular hypertrophy in the remaining single kidney","volume":"11","author":"Naik","year":"2021","journal-title":"Sci Rep."},{"issue":"1","key":"B128-20260625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/jcm9010253","article-title":"Ischemia and reperfusion injury in kidney transplantation: relevant mechanisms in injury and repair","volume":"9","author":"Nieuwenhuijs-Moeke","year":"2020","journal-title":"J Clin Med."},{"issue":"8","key":"B129-20260625","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/ndt\/gft538","article-title":"Mesenchymal stromal cell therapy in conditions of renal ischaemia\/reperfusion","volume":"29","author":"Erpicum","year":"2014","journal-title":"Nephrol Dial Transplant."},{"issue":"suppl 1","key":"B130-20260625","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1166-7087(14)70058-2","article-title":"Innate and adaptive immune responses subsequent to ischemia-reperfusion injury in the kidney","volume":"24","author":"Denecke","year":"2014","journal-title":"Prog Urol."},{"issue":"3","key":"B131-20260625","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/ndt\/gfn667","article-title":"Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis","volume":"24","author":"Yarlagadda","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B132-20260625","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1038\/s41467-024-54222-0","article-title":"ATP dynamics as a predictor of future podocyte structure and function after acute ischemic kidney injury in female mice","volume":"15","author":"Takahashi","year":"2024","journal-title":"Nat Commun."},{"issue":"1","key":"B133-20260625","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12882-019-1298-x","article-title":"The role of podocyte damage in the etiology of ischemia-reperfusion acute kidney injury and post-injury fibrosis","volume":"20","author":"Chen","year":"2019","journal-title":"BMC Nephrol."},{"issue":"10","key":"B134-20260625","first-page":"1002","article-title":"[Immunosuppressive drugs and transplant protocols]","volume":"74","author":"Le\u00f3n","year":"2021","journal-title":"Arch Esp Urol."},{"issue":"4S","key":"B135-20260625","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"issue":"8","key":"B136-20260625","doi-asserted-by":"crossref","first-page":"e14190","DOI":"10.1111\/apha.14190","article-title":"Immunosuppression with cyclosporine versus tacrolimus shows distinctive nephrotoxicity profiles within renal compartments","volume":"240","author":"Demirci","year":"2024","journal-title":"Acta Physiol (Oxf)."},{"issue":"5","key":"B137-20260625","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1358\/dnp.2003.16.5.829315","article-title":"Molecular actions of calcineurin inhibitors","volume":"16","author":"Hamawy","year":"2003","journal-title":"Drug News Perspect."},{"issue":"6","key":"B138-20260625","doi-asserted-by":"crossref","first-page":"e12679","DOI":"10.14814\/phy2.12679","article-title":"Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm","volume":"4","author":"Wakamatsu","year":"2016","journal-title":"Physiol Rep."},{"issue":"9","key":"B139-20260625","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med."},{"key":"B140-20260625","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fmed.2018.00221","article-title":"Proteinuric kidney diseases: a podocyte's slit diaphragm and cytoskeleton approach","volume":"5","author":"Yu","year":"2018","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"B141-20260625","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/j.ajkd.2021.12.011","article-title":"Principles of immunosuppression in the management of kidney disease: core curriculum 2022","volume":"80","author":"Kant","year":"2022","journal-title":"Am J Kidney Dis."},{"key":"B142-20260625","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fendo.2014.00181","article-title":"Non-immunologic actions of calcineurin inhibitors in proteinuric kidney diseases","volume":"5","author":"Spurney","year":"2014","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"9","key":"B143-20260625","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2215\/CJN.01520209","article-title":"Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome","volume":"4","author":"Kengne-Wafo","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"B144-20260625","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/adc.2005.080960","article-title":"Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome","volume":"91","author":"Fujinaga","year":"2006","journal-title":"Arch Dis Child."},{"issue":"3","key":"B145-20260625","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s004670050044","article-title":"Long-term clinical and pathological effects of cyclosporin in children with nephrosis","volume":"14","author":"Seikaly","year":"2000","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"B146-20260625","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct Target Ther."},{"issue":"6","key":"B147-20260625","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice","volume":"121","author":"Inoki","year":"2011","journal-title":"J Clin Invest."},{"issue":"3","key":"B148-20260625","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1681\/ASN.2011070690","article-title":"Inhibition of MTOR disrupts autophagic flux in podocytes","volume":"23","author":"Cin\u00e0","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B149-20260625","first-page":"2495","article-title":"Role of mTOR signaling in the regulation of high glucose-induced podocyte injury","volume":"17","author":"Li","year":"2019","journal-title":"Exp Ther Med."},{"issue":"2S suppl 1","key":"B150-20260625","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/TP.0000000000001729","article-title":"mTOR inhibition and kidney diseases","volume":"102","author":"Ma","year":"2018","journal-title":"Transplantation."},{"issue":"6","key":"B151-20260625","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell."},{"issue":"11","key":"B152-20260625","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/01.tp.0000282866.92367.99","article-title":"The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat","volume":"84","author":"Vogelbacher","year":"2007","journal-title":"Transplantation."},{"issue":"11","key":"B153-20260625","doi-asserted-by":"crossref","first-page":"e80340","DOI":"10.1371\/journal.pone.0080340","article-title":"Cellular effects of everolimus and sirolimus on podocytes","volume":"8","author":"M\u00fcller-Krebs","year":"2013","journal-title":"PLoS One."},{"issue":"3","key":"B154-20260625","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00467-015-3116-4","article-title":"Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?","volume":"31","author":"M\u00fcller-Deile","year":"2016","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"B155-20260625","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00467-014-2957-6","article-title":"Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis","volume":"30","author":"Garin","year":"2015","journal-title":"Pediatr Nephrol."},{"issue":"25","key":"B156-20260625","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N Engl J Med."},{"issue":"1","key":"B157-20260625","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ekir.2017.08.013","article-title":"Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome","volume":"3","author":"Trachtman","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"4","key":"B158-20260625","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"B159-20260625","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2215\/CJN.0000000000000411","article-title":"Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients","volume":"19","author":"Divard","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"B160-20260625","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.transproceed.2017.05.013","article-title":"Late conversion to belatacept after kidney transplantation: outcome and prognostic factors","volume":"49","author":"D\u00fcrr","year":"2017","journal-title":"Transpl Proc."},{"issue":"3","key":"B161-20260625","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/ajt.15229","article-title":"Belatacept in renal transplant recipient with mild immunologic risk factor: a pilot prospective study (BELACOR)","volume":"19","author":"Leibler","year":"2019","journal-title":"Am J Transplant."},{"issue":"12","key":"B162-20260625","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin Inhibitor- to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B163-20260625","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/TP.0000000000002192","article-title":"Conversion to belatacept in maintenance kidney transplant patients: a retrospective multicenter European Study","volume":"102","author":"Darres","year":"2018","journal-title":"Transplantation."},{"key":"B164-20260625","doi-asserted-by":"crossref","first-page":"1491514","DOI":"10.3389\/fimmu.2024.1491514","article-title":"Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients","volume":"15","author":"Efe","year":"2024","journal-title":"Front Immunol."},{"issue":"11","key":"B165-20260625","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/tri.13718","article-title":"Impact of belatacept conversion on kidney transplant function, histology, and gene expression - a single-center study","volume":"33","author":"Gupta","year":"2020","journal-title":"Transpl Int."},{"issue":"4","key":"B166-20260625","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semnephrol.2012.06.009","article-title":"The renin-angiotensin-aldosterone system in podocytes","volume":"32","author":"Wennmann","year":"2012","journal-title":"Semin Nephrol."},{"issue":"3","key":"B167-20260625","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ndt\/gfp581","article-title":"Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET","volume":"25","author":"Philipp","year":"2010","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B168-20260625","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1681\/ASN.2005090955","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation","volume":"17","author":"Heinze","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B169-20260625","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","article-title":"Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial","volume":"4","author":"Knoll","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"B170-20260625","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40620-017-0378-x","article-title":"Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment","volume":"30","author":"Ponticelli","year":"2017","journal-title":"J Nephrol."},{"issue":"11","key":"B171-20260625","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/00007890-200112150-00013","article-title":"Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril","volume":"72","author":"Midtvedt","year":"2001","journal-title":"Transplantation."},{"issue":"7","key":"B172-20260625","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/1947-2714.187141","article-title":"The effect of renin-angiotensin system inhibitors on kidney allograft survival: a systematic review and meta-analysis","volume":"8","author":"Cheungpasitporn","year":"2016","journal-title":"N Am J Med Sci."},{"issue":"10166","key":"B173-20260625","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"key":"B174-20260625","doi-asserted-by":"crossref","first-page":"712671","DOI":"10.3389\/fmed.2021.712671","article-title":"Sodium-glucose cotransporter-2 inhibitor (SGLT2i) as a primary preventative agent in the healthy individual: a need of a future randomised clinical trial?","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"19","key":"B175-20260625","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.3390\/ijms231911203","article-title":"Changes in proximal tubular reabsorption modulate microvascular regulation via the TGF system","volume":"23","author":"Poursharif","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"5","key":"B176-20260625","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360."},{"key":"B177-20260625","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B178-20260625","doi-asserted-by":"crossref","first-page":"101878","DOI":"10.1016\/j.mito.2024.101878","article-title":"The interplay between sodium\/glucose cotransporter type 2 and mitochondrial ionic environment","volume":"76","author":"Borriello","year":"2024","journal-title":"Mitochondrion."},{"issue":"1","key":"B179-20260625","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13287-025-04358-7","article-title":"Combining sodium-glucose co-transporter-2 inhibitor with mesenchymal stem cells and brown adipose tissue (BAT) and white adipose tissue (WAT) transplantation to mitigate the progression of diabetic kidney disease: a pre-clinical approach","volume":"16","author":"Beyerstedt","year":"2025","journal-title":"Stem Cell Res Ther."},{"issue":"17","key":"B180-20260625","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation."},{"issue":"5S","key":"B181-20260625","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"Kidney disease: improving global outcomes diabetes work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"issue":"4S","key":"B182-20260625","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"B183-20260625","doi-asserted-by":"crossref","first-page":"1332397","DOI":"10.3389\/fneph.2024.1332397","article-title":"SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations","volume":"4","author":"Polychronopoulou","year":"2024","journal-title":"Front Nephrol."},{"issue":"4","key":"B184-20260625","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdi.12760","article-title":"No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: a meta-analysis","volume":"9","author":"Cai","year":"2018","journal-title":"J Diabetes Investig."},{"issue":"5","key":"B185-20260625","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5500\/wjt.v13.i5.239","article-title":"Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients","volume":"13","author":"Ramakrishnan","year":"2023","journal-title":"World J Transplant."},{"issue":"10","key":"B186-20260625","doi-asserted-by":"crossref","first-page":"e230284","DOI":"10.1530\/EC-23-0284","article-title":"Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy","volume":"12","author":"Shi","year":"2023","journal-title":"Endocr Connect."},{"issue":"2","key":"B187-20260625","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"5","key":"B188-20260625","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2213-8587(24)00371-1","article-title":"GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study","volume":"13","author":"Orandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"B189-20260625","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1523-1755.1999.00503.x","article-title":"Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus","volume":"56","author":"Yan","year":"1999","journal-title":"Kidney Int."},{"issue":"3","key":"B190-20260625","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41581-020-00339-6","article-title":"Nuclear receptors in podocyte biology and glomerular disease","volume":"17","author":"Agrawal","year":"2021","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"B191-20260625","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1096\/fj.01-0681com","article-title":"Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction","volume":"16","author":"Smoyer","year":"2002","journal-title":"FASEB J."},{"issue":"6","key":"B192-20260625","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/j.1523-1755.2005.00723.x","article-title":"Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization","volume":"68","author":"Ransom","year":"2005","journal-title":"Kidney Int."},{"issue":"1","key":"B193-20260625","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1038\/s41598-017-06810-y","article-title":"Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1","volume":"7","author":"McCaffrey","year":"2017","journal-title":"Sci Rep."},{"issue":"10","key":"B194-20260625","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jcp.52.10.735","article-title":"Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation","volume":"52","author":"Bailey","year":"1999","journal-title":"J Clin Pathol."},{"issue":"2 Pt 2","key":"B195-20260625","first-page":"F240","article-title":"Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney","volume":"268","author":"Simon","year":"1995","journal-title":"Am J Physiol."},{"issue":"6","key":"B196-20260625","doi-asserted-by":"crossref","first-page":"F1656","DOI":"10.1152\/ajprenal.00275.2009","article-title":"The balance of autocrine VEGF-A and VEGF-C determines podocyte survival","volume":"297","author":"M\u00fcller-Deile","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"issue":"10-11","key":"B197-20260625","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/PL00013420","article-title":"Treatment of FSGS with plasma exchange and immunadsorption","volume":"14","author":"Franke","year":"2000","journal-title":"Pediatr Nephrol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:58:05Z","timestamp":1786478285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":197,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001091","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}